Study author of SPOT-MAS clinical validation – a ctDNA-based assay for multi-cancer detection – to present at 2023 ASCO Breakthrough Official Press Program – Yokohama, Japan.

 

Thursday, August 3 at 12:00-13:00 JST

Location: Pacifico Yokohama.

The American Society of Clinical Oncology is a leading, global society of more than 45,000 oncology professionals in over 150 countries.

This year ASCO Breakthrough Meeting in Yokohama, Japan brings the world’s top oncology professionals to reveal how utting-edge advances in cancer care technology and innovations can help transform cancer care.

Out of 160 abstracts being presented in Yokohama, four abstracts were chosen for ASCO Official Press Program.

Besides 03 authors from Japan, China and Australia, Dr. Le Son Tran from the Medical Genetics Institute of Ho Chi Minh City, Vietnam will discuss an interim report of the clinical validation of SPOT-MAS, an ctDNA-based assay for multi-cancer detection.

Dr. Le Son Tran will share the latest updates from the research as well as highlighting key findings. The Abstract “Clinical validation of a ctDNA-based assay for multi-cancer detection:  A Vietnamese longitudinal prospective cohort study of 2,795 participants” will also be presented at the Poster Session B, Aug 4.

Keep in touch with us to learn more about key findings and ASCO experts’ opinion after the session.

—

Dr. Le Son Tran – Senior Scientist at Medical Genetics Institute, Ho Chi Minh City is the leading researcher of the SPOT-MAS assay, a multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization.

The SPOT-MAS assay contributes 02 abstracts at this year ASCO Breakthrough, while another abstract of Minimal Residual Disease (MRD) “Personalized K-Track Assay to Detect Actionable Mutations and Minimal Residual Disease in Solid Tumors” from study author Dr. Lan Tu, Prinicipal Investigator (R&D) of Gene Solutions received an Abstract Award (Top 40 highest scoring abstracts submitted to the 2023 ASCO Breakthrough Meeting).

ASCO Breakthrough is endorsed by the Japan Ministry of Health, Labor, and Welfare.

Previously, another study from Dr. Le Son Tran was also highlighted at eLife Science press release after the Reviewed Preprint “Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization” published.

https://elifesciences.org/for-the-press/63ced096/new-circulating-tumour-dna-test-measures-multiple-markers-to-detect-cancer-early

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More